Shots:

• Oxford Biomedica has joined the consortium- which is led by the Jenner Institute- University of Oxford and also includes the VMIC- Pall Life Sciences- Cobra Biologics- and Halix BV to rapidly develop- scale-up and manufacture a vaccine (ChAdOx1 nCov-19) against COVID-19
• The ChAdOx1 nCOV-19 vaccine is anticipated to be the UK’s first COVID-19 vaccine in clinical studies to be initiated in later Apr’2020. The consortium has recruited individuals aged 18-55yrs. from the Thames Valley area in the UK to evaluate the safety and efficacy of the vaccine
• Oxford Biomedica will allow the consortium access to its large scale GMP manufacturing facilities for viral vectors- including its new Oxbox facility. ChAdOx1 is based on adenoviral vector technology and has demonstrated positive results in pre/ clinical studies conducted to date

Click here to­ read full press release/ article | Ref: Oxford Biomedica | Image: The Pharma Letter